Literature DB >> 10611636

Endogenous DA-mediated feedback inhibition of DA neurons: involvement of both D(1)- and D(2)-like receptors.

W X Shi1, C L Pun, P L Smith, B S Bunney.   

Abstract

To investigate the role of D(1)-like receptors in endogenous dopamine (DA)-mediated feedback control of DA neurons in vivo, single unit recordings were made from rat nigral DA cells using low cerveau isolé preparations. The D(2) antagonist raclopride, but not the D(1) antagonist SCH23390, increased baseline activity of DA neurons, suggesting that spontaneously released DA acts primarily through D(2)-like receptors to inhibit DA cells. However, feedback inhibition induced by an increased DA release by D-amphetamine (1 mg/kg, i.v.) was partially reversed by SCH23390. The same inhibition, on the other hand, was always completely reversed by raclopride, suggesting that the D(1)-mediated portion of the inhibition depends upon co-activation of D(2)-like receptors. In rats with forebrain hemitransections, D-amphetamine-induced inhibition was markedly decreased and the remaining inhibition was not blocked by SCH23390, supporting the suggestion that D(1)-D(2) co-activation-induced inhibition is mediated through long feedback pathways. In chloral hydrate-anesthetized rats, D-amphetamine-induced inhibition was also insensitive to SCH23390; however, the degree of the inhibition was not reduced. Combined with previous studies, these data suggest that chloral hydrate not only inactivates the D(1) feedback pathway but also enables the D(2) feedback pathway to operate independently of D(1)-like receptors. Conversely, in parkinsonian animals D(1) receptor activation alone has been reported to inhibit DA cells. Taken together, these results suggest that a major portion of endogenous DA-mediated feedback inhibition is due to concurrent activation of D(1)- and D(2)-like receptors. However, this D(1)-D(2) interdependence may alter under certain conditions and may play a role in the pathophysiology of Parkinson's disease. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10611636     DOI: 10.1002/(SICI)1098-2396(200002)35:2<111::AID-SYN3>3.0.CO;2-7

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  13 in total

1.  Lateral preoptic and ventral pallidal roles in locomotion and other movements.

Authors:  Suriya Subramanian; Rhett A Reichard; Hunter S Stevenson; Zachary M Schwartz; Kenneth P Parsley; Daniel S Zahm
Journal:  Brain Struct Funct       Date:  2018-04-26       Impact factor: 3.270

2.  D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell.

Authors:  B Kalyanasundar; Claudia I Perez; Alvaro Luna; Jessica Solorio; Mario G Moreno; David Elias; Sidney A Simon; Ranier Gutierrez
Journal:  J Neurophysiol       Date:  2015-05-13       Impact factor: 2.714

3.  Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors.

Authors:  W X Shi; C L Pun; X X Zhang; M D Jones; B S Bunney
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

4.  Withdrawal from Acute Amphetamine Induces an Amygdala-Driven Attenuation of Dopamine Neuron Activity: Reversal by Ketamine.

Authors:  Pauline Belujon; Nicole L Jakobowski; Hannah K Dollish; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2015-07-01       Impact factor: 7.853

5.  Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.

Authors:  H L Melrose; J C Dächsel; B Behrouz; S J Lincoln; M Yue; K M Hinkle; C B Kent; E Korvatska; J P Taylor; L Witten; Y-Q Liang; J E Beevers; M Boules; B N Dugger; V A Serna; A Gaukhman; X Yu; M Castanedes-Casey; A T Braithwaite; S Ogholikhan; N Yu; D Bass; G Tyndall; G D Schellenberg; D W Dickson; C Janus; M J Farrer
Journal:  Neurobiol Dis       Date:  2010-07-24       Impact factor: 5.996

6.  Chronic administration of methylphenidate produces neurophysiological and behavioral sensitization.

Authors:  Pamela B Yang; Alan C Swann; Nachum Dafny
Journal:  Brain Res       Date:  2007-02-02       Impact factor: 3.252

7.  Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action.

Authors:  J E Olijslagers; T R Werkman; A C McCreary; C G Kruse; W J Wadman
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

8.  LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors.

Authors:  Kelly M Hinkle; Mei Yue; Bahareh Behrouz; Justus C Dächsel; Sarah J Lincoln; Erin E Bowles; Joel E Beevers; Brittany Dugger; Beate Winner; Iryna Prots; Caroline B Kent; Kenya Nishioka; Wen-Lang Lin; Dennis W Dickson; Christopher J Janus; Matthew J Farrer; Heather L Melrose
Journal:  Mol Neurodegener       Date:  2012-05-30       Impact factor: 14.195

Review 9.  Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder.

Authors:  Mostafa El Mansari; Bruno P Guiard; Olga Chernoloz; Ramez Ghanbari; Noam Katz; Pierre Blier
Journal:  CNS Neurosci Ther       Date:  2010-04-08       Impact factor: 5.243

10.  Dopaminergic basis for signaling belief updates, but not surprise, and the link to paranoia.

Authors:  Matthew M Nour; Tarik Dahoun; Philipp Schwartenbeck; Rick A Adams; Thomas H B FitzGerald; Christopher Coello; Matthew B Wall; Raymond J Dolan; Oliver D Howes
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.